Center-Authored Papers

Filters: Author is Keating, Michael J  [Clear All Filters]
Journal Article
Yin Q, Sivina M, Robins H, Yusko E, Vignali M, O'Brien S, Keating MJ, Ferrajoli A, Estrov Z, Jain N et al..  2017.  Ibrutinib Therapy Increases T Cell Repertoire Diversity in Patients with Chronic Lymphocytic Leukemia.. Journal of immunology (Baltimore, Md. : 1950). Abstract
Coutré SE, Barrientos JC, Brown JR, de Vos S, Furman RR, Keating MJ, Li D, O'Brien SM, Pagel JM, Poleski MH et al..  2015.  Management of adverse events associated with idelalisib treatment: expert panel opinion.. Leukemia & lymphoma. :1-8. Abstract
Tsimberidou A-M, Kantarjian HM, Wen S, Keating MJ, O'Brien S, Brandt M, Pierce S, Freireich EJ, Medeiros JL, Estey E.  2008.  Myeloid sarcoma is associated with superior event-free survival and overall survival compared with acute myeloid leukemia.. Cancer. 113(6):1370-8. Abstract
Tsimberidou AM, Keating MJ, Jabbour EJ, Ravandi-Kashani F, O'Brien S, Estey E, Bekele N, Plunkett WK, Kantarjian H, Borthakur G.  2014.  A Phase I Study of Fludarabine, Cytarabine, and Oxaliplatin Therapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia.. Clinical lymphoma, myeloma & leukemia. 14(5):395-400.e1. Abstract
Tsimberidou A-M, Kantarjian HM, Wen S, O'Brien S, Cortes J, Wierda WG, Koller C, Pierce S, Brandt M, Freireich EJ et al..  2008.  The prognostic significance of serum beta2 microglobulin levels in acute myeloid leukemia and prognostic scores predicting survival: analysis of 1,180 patients.. Clinical cancer research : an official journal of the American Association for Cancer Research. 14(3):721-30. Abstract